Related Experiment Video
Updated: Jul 5, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Sudden onset of diabetic ketoacidosis during consensus interferon therapy for chronic viral hepatitis C
Eric S Nylen1, Ira C Marathe, Irfan A Khan
1Department of Endocrinology, Veterans Affairs Medical Center, George Washington University Medical Center, Washington, DC 20422, USA. eric.nylen@med.va.Gov
Introduction:
Interferon (IFN)-alpha, used for the treatment of chronic hepatitis C, has rarely been associated with the development of diabetes. Consensus interferon (CIFN), which is used for nonresponders, has not been associated with this complication. We describe the first case of new onset diabetes in a patient on CIFN.
Case:
A 50-year-old man with chronic hepatitis C and no prior diabetes was started on IFN-alpha. After 24 weeks with a detectable viral load, he was switched to CIFN. Four weeks later, he presented in diabetic ketoacidosis which resolved with appropriate therapy without any ascertainable etiology (glutamic acid decarboxylase negative). Within 9 months he was off insulin, and is off all diabetic medications with an HgA1c of 5.6% 2 years after the episode.
Related Concept Videos
Diabetic Ketoacidosis l: Introduction
Diabetic Ketoacidosis ll: Pathophysiology
Viral Hepatitis I: Introduction
Hepatitis
Inhibitors of Viral Protein Synthesis
Chronic Pancreatitis II: Collaborative Care
Assessment:
